gives little light on its pension liabilities. "There are lots of questions that will come up in the next 5 years there." The video also sheds a good deal more color on two Price longs: Hospira ( HSP ) and Hess ( HES ). 3 comments!
Institute Contributors : By Christopher R. Pavese, CFA Earlier this month, we outlined our investment thesis in shares of Hospira ( HSP ), which can be found here (PDF). Since publishing our report, HSP has appreciated rapidly over the past few weeks
Hospira ( HSP +1.2% ) says results from a post-marketing study of the company's European biosimilar epoetin, Retacrit, met its
May 30 (Reuters) - Hospira Inc said it received a warning letter from the U.S. Food and Drug Administration raising concerns about contamination of drugs manufactured at its facility in India.
(Reuters) - A federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc .
May 20 (Reuters) - A U.S. federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc .
Cubist Pharmaceuticals ( CBST +11.3% ) spikes to session highs. The move appears relates to an apparent Markman ruling on Hospira (HSP +0.7% , which has a generic version of Cubist's drug Cubicin. Seeking Alpha contributor PropThink noted last week
up 33% in the same period. The key to CBST's stagnation is an ongoing patent challenge by generic drug manufacturer Hospira ( HSP ) on Cubists' primary revenue driver Cubicin (daptomycin), an injectable antibiotic that's expected to achieve
continue in the long run. While we anticipate biosimilar competition to impact Epogen and Neupogen in the U.S. in 2014 (from Hospira and Teva), we expect Epogen and Aranesp to see stronger sales in the near term, particularly over the next two years, following
almost half of its U.S. infusion pump market share because of a product recall, and regaining share from CareFusion and Hospira will be an uphill battle. More than two thirds of Baxter's revenue stems from market-leading products, a tribute to its